We are live on ! Find out more
LLY icon

Eli Lilly

1,247 hedge funds and large institutions have $69.4B invested in Eli Lilly in 2017 Q2 according to their latest regulatory filings, with 79 funds opening new positions, 420 increasing their positions, 495 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 69

0.25% more ownership

Funds ownership: 76.19%76.43% (+0.25%)

0% less funds holding

Funds holding: 1,2501,247 (-3)

2% less capital invested

Capital invested by funds: $70.7B → $69.4B (-$1.34B)

8% less funds holding in top 10

Funds holding in top 10: 2624 (-2)

15% less repeat investments, than reductions

Existing positions increased: 420 | Existing positions reduced: 495

28% less call options, than puts

Call options by funds: $384M | Put options by funds: $534M

Holders
1,247
Holders Change
-3
Holders Change %
-0.24%
% of All Funds
31%
Holding in Top 10
24
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-7.69%
% of All Funds
0.6%
New
79
Increased
420
Reduced
495
Closed
69
Calls
$384M
Puts
$534M
Net Calls
-$150M
Net Calls Change
-$50.3M

LLY Hedge Fund Activity: Q2 2017 in Review

1,247 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2017, worth a combined $69.4B — down 1.9% from $70.7B a quarter earlier.

Buyers outnumbered sellers: 79 funds opened new LLY positions and 69 closed out — a net gain of 10 holders — while 420 added to existing stakes and 495 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $752M. The largest seller was Citadel Advisors, cutting an estimated $217M.

  • 1,247 institutional investors held Eli Lilly (LLY) as of Q2 2017, down from 1,250 in Q1 2017.
  • Funds reported $69.4B of Eli Lilly stock for Q2 2017, down 1.9% quarter-over-quarter.
  • 79 funds opened new Eli Lilly positions in Q2 2017 and 69 closed out, a net change of +10 holders.
  • The largest Eli Lilly buyer in Q2 2017 was Janus Henderson Group, an estimated $752M added.
  • The largest Eli Lilly seller in Q2 2017 was Citadel Advisors, an estimated $217M sold.

Based on aggregated 13F filings for Q2 2017.